About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arcus Biosciences

< Previous 1 2 3 4 Next >
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
From Arcus Biosciences
Via Business Wire
Tickers RCUS
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
From Arcus Biosciences
Via Business Wire
Tickers RCUS
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Tickers RCUS
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
From Arcus Biosciences
Via Business Wire
Tickers RCUS
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.